AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04324541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET scan of the brain with Flortaucipir
Description: PET scan of the brain with non FDA approved Radio tracer.
Study NCT03574376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Liposome Injection
Description: Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
Study NCT03574376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
Study NCT04257968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: carotid ultrasonography (IMT and elastography)
Study NCT04257968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI of carotid artery and brain
Study NCT04257968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuro Psychological Assessment Battery
Description: Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV
Study NCT04257968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Questionaires
Description: Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
Study NCT04479059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follicular fluid flushing
Description: Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
Study NCT03397524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optima4BP
Description: optima4BP will provide the treating physician with a treatment action recommendation for consideration.
Study NCT00232284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sertraline
Description: RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
Study NCT00232284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
Study NCT00232284 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: An integrated 10-week CBT program for depression/anxiety and comorbid substance use
Study NCT00232284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: An integrated 10-week CBT program for depression/anxiety and comorbid substance use
Study NCT03844386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv4
Description: viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
Study NCT03844386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
Study NCT02430831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nidina
Study NCT02430831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04132700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-NRG Metobolic Cart Device
Description: ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
Study NCT01194817 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flexion Knee Replacement System using Cemented Fixation
Study NCT01194817 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flexion Knee Replacement System using Cementless Fixation
Study NCT02454127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Atkins Diet
Description: Dietary counseling for 1 year
Study NCT02454127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zone Diet
Description: Dietary counseling for 1 year
Study NCT02454127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers Diet
Description: Dietary counseling for 1 year
Study NCT02454127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ornish Diet
Description: Dietary counseling for 1 year
Study NCT01977274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gynecological cancer
Description: blood and tumor samples
Study NCT03358186 — intervention group
Intervention type: PROCEDURE
Intervention: surgically treated periprosthetic femur fracture
Description: patients with surgically treated periprosthetic femur fracture
Study NCT04572906 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NTX-001
Description: One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
Study NCT03890289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
Study NCT03890289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants received intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Participants received intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Participants received etoposide 50 mg/m\^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Participants received etoposide 50 mg/m\^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants received pemetrexed at a dose of 500 mg/m\^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants received pemetrexed at a dose of 500 mg/m\^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants received carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants received carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants received paclitaxel intravenously at a dose of 45 mg/m\^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants received paclitaxel intravenously at a dose of 45 mg/m\^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: In combination with etoposide, participants received cisplatin 50 mg/m\^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants received cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
Study NCT03840902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: In combination with etoposide, participants received cisplatin 50 mg/m\^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants received cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
Study NCT03840902 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Participants received IMRT 5 fractions per week for about 6 weeks (Total 60 gray \[Gy\]).
Study NCT03840902 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Participants received IMRT 5 fractions per week for about 6 weeks (Total 60 gray \[Gy\]).
Study NCT01576029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL (XRP6258)
Description: Pharmaceutical form: solution Route of administration: intravenous
Study NCT01576029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOCETAXEL (XRP6976)
Description: Pharmaceutical form: solution Route of administration: intravenous
Study NCT02426138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meal Delivery (MTM)
Description: Patients will receive delivery of medically tailored meals for 12 weeks
Study NCT02426138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care + Choose MyPlate
Description: Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
Study NCT02426138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care + Choose MyPlate
Description: Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
Study NCT06290791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two level lumbar decompression with BESS procedure received one drain.
Description: patients who underwent two level lumbar decompression with BESS procedure received one drain.
Study NCT06290791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two level lumbar decompression with BESS procedure received two drain.
Description: patients who underwent two level lumbar decompression with BESS procedure received two drains
Study NCT04199338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis
Description: In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test.
Study NCT03450486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: one 30 minute bout of mild exercise
Study NCT03450486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: one 30 minute bout of mild exercise
Study NCT02583113 — intervention group
Intervention type: DEVICE
Intervention: Total and Unicompartment Knee Replacement
Description: Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
Study NCT01181154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab (Mabthera®)
Description: 1000 mg at day 1 and day 15
Study NCT01181154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equivalent volume total
Study NCT03275961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training
Description: Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
Study NCT03658109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Bolus Infusion
Description: Patients will undergo Lidocaine Bolus infusion.
Study NCT03658109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL block
Description: Patients will undergo a posterior QL block pre-operatively
Study NCT03658109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Bolus Infusion
Description: Patients will undergo Saline Bolus infusion.
Study NCT03658109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simulated QL block
Description: Patients will undergo a simulated posterior QL block pre-operatively.
Study NCT04110743 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EXPLORER PET/CT
Description: Intervention: PET/CT using different protocols
Study NCT00982917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stamp-in-Safety Curriculum
Description: 30 minute curriculum on playground safety
Study NCT00982917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stamp-in-Safety curriculum
Description: 30 minute lesson on playground supervision
Study NCT01658241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: 40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
Study NCT05470231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
Study NCT05470231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
Study NCT02543281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive cardiac resynchronization therapy
Description: The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
Study NCT02543281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cardiac Resynchronization Therapy
Description: CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
Study NCT04555577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO
Study NCT04555577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04555577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT04555577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT03509909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: Manualized hatha yoga
Study NCT03509909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive physical activity
Description: Manualized stretching and strengthening
Study NCT03821506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Light
Description: Dynamic Lighting system
Study NCT03821506 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standard lighting system
Study NCT04560946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Augmented Cognitive Training (PACT)
Description: Personalized Augmented Cognitive Training (PACT) group. Intervention: Behavioral: The study neuropsychologist will use a portion of the TBI education session to describe available treatment modules and make recommendations for module selection based on results from baseline assessment. After discussion, five 60-minute CogSMART modules will be selected. PACT participants will receive guidance to complete 2 modules per week of the CogSMART app. PACT participants will also receive guidance to complete BrainHQ exercises of their choice for 30 minutes a day, 5 days per week, for a total training time of 15 hours.
Study NCT04560946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment As Usual
Description: Enhanced Treatment As Usual (ETAU) group. Intervention: Behavioral: The ETAU condition was designed to replicate treatment as usual following neuropsychological assessment of post-TBI cognitive problems. Treatment as usual for mTBI patients at the VA hospital usually consists of: 1) A general evaluation by the polytrauma clinic, 2) Possible neuropsychological assessment evaluation by the TBI Cognitive Rehabilitation Clinic, and 3) If impairments are present, cognitive rehabilitation is offered. The current study's condition is considered enhanced treatment as usual because standard of care for chronic mTBI does not always involve neuropsychological assessment with feedback and psychoeducation or the provision of self-directed tools such as the CogSMART app or BrainHQ cognitive training software.
Study NCT01773746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal Resuscitation
Description: CPAP or Positive Pressure Ventilation will be provided.
Study NCT01189929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.
Study NCT01189929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
Study NCT01532414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: oral, capsules, taken one time daily, for 3 months
Study NCT01189929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.